Pharmaceutical Contract Sales Organizations Market Size, Share & Trends Analysis Report By Services (Personal, Non-personal Promotion), By End-use (Pharma, Biopharma Companies), By Region, And Segment Forecasts, 2023 - 2030

Pharmaceutical Contract Sales Organizations Market Size, Share & Trends Analysis Report By Services (Personal, Non-personal Promotion), By End-use (Pharma, Biopharma Companies), By Region, And Segment Forecasts, 2023 - 2030

Pharmaceutical Contract Sales Organizations Market Growth & Trends

The global pharmaceutical contract sales organizations market size is expected to reach USD 16.3 billion by 2030, registering a CAGR of 8.4% from 2023 to 2030, according to a new report by Grand View Research, Inc. High adoption of new technologies for contract sales by pharmaceutical contract sales organizations (CSO), an increase in the interest among end-users to increase the sales of biopharmaceutical and small molecule drugs, and the surge in demand for reducing the cost associated with in-house sales are some of the key factors supporting the growth of the industry. Over the years, the number of new drug launches has increased.

For instance, according to the IQVIA report on R&D trends, 84 new active substances were launched globally in 2021, which was double as compared to the last five years. The increase in drug launches globally is expected to improve the demand for contract sales services, which is likely to support industry growth. Prescription drug sales are witnessing a steady rise. For instance, according to Evaluate Pharma, worldwide total prescription drug sales accounted for USD 1,066 billion in 2021 and will reach USD 1,612 billion by 2028. The growing demand for sales among pharmaceutical companies is expected to improve the demand for CSO services for pharmaceuticals in the post-pandemic period.

Pharmaceutical Contract Sales Organizations Market Report Highlights

  • Based on service, the personal promotion segment dominated the industry in 2022. A rise in the R&D activities of pharmaceutical companies is expected to increase the number of new drug launches, and approvals are expected to support the segment growth
  • The pharmaceutical companies end-use segment held the largest revenue share in 2022 due to the high competition among pharmaceutical companies in product sales, promoting the demand for an efficient team to support their sales activities
  • North America held the largest revenue share in 2022. A significant number of drugs were launched in the region in the previous years, especially in the U.S., which is one of the key factors supporting the region’s growth
  • Moreover, the region’s public organization is steadily focused on supporting R&D activities by providing funding. This has further supported the region’s growth
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Service
1.1.2. End-use
1.1.3. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.2. Volume price analysis (Model 2)
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
1.9.3. Objective 3
1.9.4. Objective 4
Chapter 2. Executive Summary
2.1. Market Outlook
Chapter 3. Pharmaceutical Contract Sales Organization Market (CSO) Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increase the R&D activities on drugs and increase in the drug pipeline
3.2.1.2. Growing interest of pharmaceutical companies to increase the sales of the products
3.2.1.3. Adoption of digital technologies by Pharmaceutical Contract Sales Organizations
3.2.2. Market restraint analysis
3.2.2.1. Quality issues associated with outsourcing
3.2.3. Covid-19 Impact & Recovery Analysis
3.2.4. Industry Analysis - Porter’s Five Forces
3.2.5. PESTLE Analysis
Chapter 4. Pharmaceutical Contract Sales Organization Market (CSO): Service Segment Analysis
4.1. Pharmaceutical Contract Sales Organization Market (CSO) Market: Definition & Scope
4.2. Pharmaceutical Contract Sales Organization Market (CSO) Market: Service Market Share Analysis, 2022 & 2030
4.2.1. Personal Promotion
4.2.1.1. Personal promotion market, 2018 - 2030 (USD Million)
4.2.1.2. Promotional sales team
4.2.1.2.1. Promotional sales team market, 2018 - 2030 (USD Million)
4.2.1.3. Key account management
4.2.1.3.1. Key account management market, 2018 - 2030 (USD Million)
4.2.1.4. Vacancy Management
4.2.1.4.1. Vacancy Management market, 2018 - 2030 (USD Million)
4.2.2. Non-Personal Promotion
4.2.2.1. Non-Personal promotion market, 2018 - 2030 (USD Million)
4.2.2.2. Medical affairs solutions
4.2.2.2.1. Medical affairs solutions market, 2018 - 2030 (USD Million)
4.2.2.3. Remote medical science liaisons
4.2.2.3.1. Remote medical science liaisons market, 2018 - 2030 (USD Million)
4.2.2.4. Nurse (clinical) educators
4.2.2.4.1. Nurse (clinical) educators market, 2018 - 2030 (USD Million)
4.2.2.5. Others
4.2.2.5.1. Others market, 2018 - 2030 (USD Million)
Chapter 5. Pharmaceutical Contract Sales Organization Market (CSO): End-use Segment Analysis
5.1. Pharmaceutical Contract Sales Organization Market (CSO) Market: Definition & Scope
5.2. Pharmaceutical Contract Sales Organization Market (CSO) Market: End Use Market Share Analysis, 2022 & 2030
5.2.1. Pharmaceutical Companies
5.2.1.1. Pharmaceutical companies Market, 2018 - 2030 (USD Million)
5.2.2. Biopharmaceutical Companies
5.2.2.1. Biopharmaceutical companies Market, 2018 - 2030 (USD Million)
Chapter 6. Pharmaceutical Contract Sales Organization Market (CSO): Regional Analysis
6.1. Pharmaceutical Contract Sales Organization Market (CSO): Regional market share analysis, 2022 & 2030
6.2. North America
6.2.1. North America Market estimates and forecast, 2018 - 2030
6.2.2. U.S.
6.2.2.1. U.S. Market estimates and forecast, 2018 - 2030
6.2.3. Canada
6.2.3.1. Canada Market estimates and forecast, 2018 - 2030
6.3. Europe
6.3.1. Europe Market estimates and forecast, 2018 - 2030
6.3.2. U.K.
6.3.2.1. U.K. Market estimates and forecast, 2018 - 2030
6.3.3. Germany
6.3.3.1. Germany Market estimates and forecast, 2018 - 2030
6.3.4. France
6.3.4.1. France Market estimates and forecast, 2018 - 2030
6.3.5. Italy
6.3.5.1. Italy Market estimates and forecast, 2018 - 2030
6.3.6. Spain
6.3.6.1. Spain Market estimates and forecast, 2018 - 2030
6.3.7. Denmark
6.3.7.1. Denmark Market estimates and forecast, 2018 - 2030
6.3.8. Sweden
6.3.8.1. Sweden Market estimates and forecast, 2018 - 2030
6.3.9. Norway
6.3.9.1. Norway Market estimates and forecast, 2018 - 2030
6.4. Asia Pacific
6.4.1. Asia Pacific Market estimates and forecast, 2018 - 2030
6.4.2. Japan
6.4.2.1. Japan Market estimates and forecast, 2018 - 2030
6.4.3. China
6.4.3.1. China Market estimates and forecast, 2018 - 2030
6.4.4. India
6.4.4.1. India Market estimates and forecast, 2018 - 2030
6.4.5. South Korea
6.4.5.1. South Korea Market estimates and forecast, 2018 - 2030
6.4.6. Australia
6.4.6.1. Australia Market estimates and forecast, 2018 - 2030
6.4.7. Thailand
6.4.7.1. Thailand Market estimates and forecast, 2018 - 2030
6.5. Latin America
6.5.1. Latin America Market estimates and forecast, 2018 - 2030
6.5.2. Brazil
6.5.2.1. Brazil Market estimates and forecast, 2018 - 2030
6.5.3. Mexico
6.5.3.1. Mexico Market estimates and forecast, 2018 - 2030
6.5.4. Argentina
6.5.4.1. Argentina Market estimates and forecast, 2018 - 2030
6.6.MEA
6.6.1. MEA Market estimates and forecast, 2018 - 2030
6.6.2. South Africa
6.6.2.1. South Africa Market estimates and forecast, 2018 - 2030
6.6.3. Saudi Arabia
6.6.3.1. Saudi Arabia Market estimates and forecast, 2018 - 2030
6.6.4. UAE
6.6.4.1. UAE Market estimates and forecast, 2018 - 2030
6.6.5. Kuwait
6.6.5.1. Kuwait Market estimates and forecast, 2018 - 2030
Chapter 7. Competitive Landscape
7.1. CMIC HOLDINGS Co., LTD
7.1.1.1. Company overview
7.1.1.2. Financial performance
7.1.1.3. Service benchmarking
7.1.1.4. Strategic initiatives
7.2. Axxelus
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Service benchmarking
7.2.1.4. Strategic initiatives
7.3. EPS Corporation.
7.3.1.1. Company overview
7.3.1.2. Financial performance
7.3.1.3. Service benchmarking
7.3.1.4. Strategic initiatives
7.4. QFR SOLUTIONS
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Service benchmarking
7.4.1.4. Strategic initiatives
7.5. MaBico
7.5.1.1. Company overview
7.5.1.2. Financial performance
7.5.1.3. Service benchmarking
7.5.1.4. Strategic initiatives
7.6. Mednext Pharma Private Limited
7.6.1.1. Company overview
7.6.1.2. Financial performance
7.6.1.3. Service benchmarking
7.6.1.4. Strategic initiatives
7.7. Peak Pharma Solutions Inc.
7.7.1.1. Company overview
7.7.1.2. Financial performance
7.7.1.3. Service benchmarking
7.7.1.4. Strategic initiatives
7.8. IQVIA, Inc.
7.8.1.1. Company overview
7.8.1.2. Financial performance
7.8.1.3. Service benchmarking
7.8.1.4. Strategic initiatives
7.9. Promoveo Health
7.9.1.1. Company overview
7.9.1.2. Financial performance
7.9.1.3. Service benchmarking
7.9.1.4. Strategic initiatives
7.10. Syneous Health
7.10.1.1. Company overview
7.10.1.2. Financial performance
7.10.1.3. Service benchmarking
7.10.1.4. Strategic initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings